Global PE firm. $94B AUM. 420+ companies across 43 countries. 800 Boylston St Boston. Sectors: business/financial services, consumer, healthcare, industrial, retail, tech.

Biotech-only VC building companies from formation. Kendall Square Cambridge. Co-founded Intellia, Translate Bio (acq Sanofi), Horizon (acq Amgen). Partners Bruce Booth and Jean-François Formela.

Middle-market buyout PE. Buy-and-build strategy. Healthcare, business services, technology. Boston HQ.

La Jolla-based seed/early VC. $750M+ invested across 11 funds. Life sciences and tech. Founded by Kevin Kinsella. 125+ companies. Notable: Vertex, Synaptics, Vocera, Onyx Pharma. WSJ top biotech VC. [merged from 817]: San Diego's pioneering life sciences + tech VC. Founded 1983 by Kevin Kinsella. $750M+ deployed. Separate Avalon BioVentures fund ($135M, 2022) exclusively for early-stage biotech.

Global PE mega-fund. $185B AUM. 200 Clarendon St Boston. Sectors: tech, healthcare, consumer, financial services, retail. Co-Managing Partners: John Connaughton, David Gross.

$26.8B AUM. Fund XI closed Oct 2024 at $7.8B — firm record. Middle-market buyouts. Focus: healthcare, software, consumer services. 5 co-founders still active.

Investment management and advisory for institutional investors. $500B+ advised. Founded 1973. Focus: private equity, VC, hedge funds, real assets. HQ Boston.

Middle-market PE with opportunistic credit and technology strategies. Thematic sourcing, operational improvement. Spun out of Harvard Management Company.

Biotech venture creation firm — invents and builds platform companies from scratch. Founded Moderna. 100+ companies, $100B+ aggregate value. CEO/Founder Noubar Afeyan (MIT PhD, McGill undergrad).

Boston-based alternative investment manager. Multi-strategy alternatives for institutional investors.

GMO — Boston-based value and quantitative asset manager. $50B+ AUM. Known for Jeremy Grantham's contrarian market calls. Long-only and alternatives.

Alternative asset manager. $10B+ AUM. Lower middle market PE, early-stage VC, public market strategies. Focused on inefficient markets.

Non-profit strategic investment arm of the US intelligence community (CIA/IC). CEO: Steve Bowsher (since Dec 2023). 200+ portfolio companies. Singapore office opened Dec 2023. Two parallel tracks — Technology and Venture — with separate reporting lines but shared deal collaboration: the tech track identifies and evaluates technologies; the venture track manages investments and portfolio.

Massachusetts state-backed VC for early-stage MA tech and life sciences startups. Seed focus. Operates alongside SBIR program.

Growth PE firm. Focus: financial services, education, business services. Boston HQ.

Boston multi-stage VC across healthcare and enterprise software. Backed Veracode, Obalon, Freenome. Partners Terry McGuire and Amir Nashat.